Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hallmark QUAD: Asunaprevir and Daclatasvir with P/R in HCV Genotype 1 or 4
NCT01573351Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of asunaprevir and daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at Post-Treatment Week 12. Started May 2012; status: completed.
02
Drugs
asunaprevirdaclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01573351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01573351.